（来源：淘金ETF） 1. 中国卫通（601698） 作为卫星通信运营国家队，手握稀缺轨位与频谱资源，是商业航天从上天到变现的关键枢纽。在低轨星 座加速组网、手机直连卫星需求爆发的背景下，卫星通信运营与数据服务成为核心增长极。凭借完整地 面站网络与高通量卫星资源，深度绑定国家星网工程，承接卫星互联网、应急通信、偏远地区覆盖等核 心订单，现金流稳定且可持续。随着商业航天规模化落地，卫星运维、数据分发、行业应用需求持续释 放，叠加政策对卫星互联网的战略支持，长期成长逻辑清晰。在空天地一体化建设浪潮中，凭借资源壁 垒与运营优势，成为商业航天运营端最具确定性的核心标的，业绩与估值具备向上空间。 2. 中国卫星（600118） 深耕卫星研制与应用全产业链，覆盖通信、导航、遥感等多领域卫星制造，是商业航天卫星制造端的核 心力量。随着低轨星座建设进入高峰期，微小卫星批量发射需求激增，卫星总装与核心部件配套迎来爆 发式增长。依托航天科技集团技术与资源优势，在卫星平台、载荷研发、总装测试等环节具备深厚积 累，深度参与国家重大航天工程与商业卫星项目。同时积极布局卫星应用服务，构建"制造+运营+数 据"闭环，拓展行业应用场景。在商 ...

Investment Rating - The industry investment rating is upgraded to "Overweight" [3] Core Insights - The chemical industry is expected to experience a recovery driven by both cyclical and growth factors, with a focus on organic silicon, PTA, polyester filament, caprolactam, spandex, vitamins, sweeteners, refrigerants, and phosphorus chemicals [7] - The organic silicon industry is entering a recovery phase, with new applications becoming the core growth driver. From 2019 to 2024, domestic DMC capacity expanded rapidly, leading to temporary oversupply and declining prices. However, with no new capacity expected in 2025 and increasing demand from sectors like new energy vehicles and photovoltaics, the supply-demand balance is improving [7] - The PTA and polyester filament industries are approaching a turning point, with the expansion cycle nearing its end. The demand side is expected to continue growing, supported by easing trade tensions and improved external demand [7] - The introduction of quota policies is expected to lead refrigerants into a high prosperity cycle, with supply constraints and stable demand growth from markets like heat pumps and cold chain logistics [9] - The synthetic biology sector is poised for explosive growth, driven by the transition to low-energy products and breakthroughs in non-grain bio-based materials [9] - OLED technology is accelerating its penetration into various display sizes, supported by policy measures aimed at fostering the new display industry [10] - The demand for high-frequency and low-loss electronic resins is increasing due to the rise of AI infrastructure, with AI server shipments expected to grow significantly [11] - The electronic chemicals sector is benefiting from the expansion of wafer production capacity, with increasing demand for key materials like photoresists and packaging materials [12] Summary by Sections Industry Performance - The chemical sector's overall performance ranked 14th with a weekly change of 0.78%, outperforming the Shanghai Composite Index by 0.38 percentage points [6][21] - Key stocks such as Honghe Technology and Zhongcai Technology saw significant price increases due to rising demand in AI servers and high-speed network equipment [6] Supply-Side Tracking - A total of 155 companies in the chemical industry had their production capacities affected, with 4 new repairs and 7 restarts reported [14] Key Industry Dynamics - BlueStar announced the acquisition of Elkem's core organic silicon assets, marking a strategic move to enhance its position in the global organic silicon industry [34] - The first biofuel blending policy in China was approved, allowing for local blending and reducing reliance on imports [34]

【市场复盘】 【机构观点】 西南证券认为，全球视角来看，化工行业已经处于新一轮景气周期的起点。我国化工企业在过去几年从 做大到做强，具备了更为坚实的利润基础和更为可观的利润弹性。展望2026年，美国进入降息通道，经 济出现衰退的风险较小，而我国2026年重点经济工作中将提振内需放在任务首位，政策工具充足，所以 认为2026年化工行业的供需改善有望超预期。 1. 上一交易日，INE主力原油期货收跌1.60元/桶，跌幅0.33%，报488.30元/桶；相关成品油主力期货高 硫燃料油收跌10.00元/吨，跌幅0.34%，报2943.00元/吨；低硫燃料油收跌41.00元/吨，跌幅1.18%，报 3436.00元/吨。 2. 上一交易日，天胶主力合约收涨2.10%，20号胶主力收涨2.34%，上海现货价格上调至16300元/吨附 近，基差持稳。节中外盘胶价上涨叠加原油走高，预计橡胶类品质表现延续偏强震荡，后续关注库存拐 点以及产区动态。 3. 上一交易日，乙二醇主力合约上涨，涨幅0.38%。供应端方面，CCF数据显示，乙二醇装置整体变化 不大，其中几套EO-EG联产装置在春节期间有不同程度的调整。3月份进口预计环比下 ...

在AI算力（核心股）需求爆发、高带宽存储器（HBM）技术迭代加速的背景下，A股HBM（高带宽存 储器）产业链今日迎来集体爆发，从上游材料、设备到封装测试，各环节个股纷纷走强，资金关注度持 续提升。拓荆科技、宏昌电子、精智达、联瑞新材、芯碁微装领涨，板块产业链相关企业整理如下： 拓荆科技（688072.SH） 宏昌电子（603002.SZ） 最新股价：11.54元 日涨幅：+8.97% 核心看点：国内电子级环氧树脂龙头，电子级环氧树脂是HBM建设所需材料环氧塑封料的上游，为 HBM封装提供关键基材支撑。 精智达（688627.SH） 最新股价：313.00元 日涨幅：+7.28% 最新股价：360.00元 日涨幅：+9.98% 核心看点：拟减持；国内ALD设备主要供应商之一，ALD沉积在HBM工艺中不可或缺，设备广泛应用 于HBM制造的关键环节。 核心看点：根据新技术和新应用在半导体（核心股）存储器方面的新要求，配合客户业务稳步推进开发 针对如HBM等新一代半导体存储器测试需求的测试技术和设备，为客户提供可应用于HBM领域的完整 测试方案。 联瑞新材（688300.SH） 最新股价：68.50元 日涨幅：+6. ...

Core Insights - The biochar market in China is projected to reach 16.055 billion yuan by 2025, with the agricultural sector accounting for 9.994 billion yuan and the energy and environmental sectors contributing 6.061 billion yuan [10][11]. Group 1: Biochar Industry Overview - Biochar is a solid material rich in carbon, produced from biomass through pyrolysis under low oxygen conditions, typically at temperatures below 700°C [2][3]. - The primary components of biochar include carbon, hydrogen, oxygen, and nitrogen, with carbon content exceeding 70% [2][3]. - Biochar is derived from various organic waste materials, including agricultural residues like chicken manure, pig manure, wood chips, and straw, as well as industrial organic waste and urban sludge [2][3]. Group 2: Biochar Production Methods - Biochar production methods are categorized into traditional kiln methods and industrial slow pyrolysis, with significant differences in efficiency and environmental impact [4][5]. - Traditional methods involve low-cost, simple operations but result in lower carbonization rates and environmental pollution due to unprocessed emissions [4][5]. - Industrial slow pyrolysis offers higher efficiency, standardized processes, and better product quality, suitable for large-scale production and high-value applications [4][5]. Group 3: Policy Background - China has introduced a series of policies to support the biochar industry, focusing on production standardization, resource utilization, and carbon credit valuation [6][7]. - Key policies include the GB/T44290-2024 standard for biochar carbon accounting and the TCAMIE37-2025 standard for defining biochar and regulating production technology [6][7]. Group 4: Biochar Industry Chain - The biochar industry chain consists of upstream biomass raw materials, midstream biochar manufacturers, and downstream application scenarios primarily in agriculture and environmental remediation [8]. - Key players in the midstream include companies like Wanrong Technology, SEEK, and Shengquan Group, which utilize pyrolysis technology to convert raw materials into biochar products [8]. Group 5: Current Development Status - The biochar industry in China is experiencing rapid growth driven by carbon neutrality goals, agricultural transformation, and enhanced environmental policies [9][10]. - By 2025, biochar production is expected to reach 54,700 tons, with demand at 52,500 tons, indicating a balanced supply-demand scenario [12]. Group 6: Competitive Landscape - The biochar production sector in China is characterized by a large number of medium-sized enterprises, leading to a competitive market with no dominant players [13][14]. - Companies like Shengquan Group are expanding their production capabilities, with significant revenue growth projected for 2024 [14][15]. Group 7: Future Trends - The biochar industry is shifting towards market-oriented carbon asset development, with policies supporting carbon credit projects [16]. - There is a growing trend towards high-value applications of biochar, including functional fertilizers and water treatment materials, driven by emerging market demands [16].

Core Viewpoint - The company, Jinan Shengquan Group Co., Ltd., plans to acquire a 13.50% stake in its subsidiary, Jinan Shangbo Pharmaceutical Co., Ltd., from BIOSYNTH LIMITED for a total consideration of $4.29 million, increasing its ownership from 76.50% to 90.00% [2][4][30]. Group 1: Transaction Overview - The acquisition aims to enhance the synergy between fine chemicals and pharmaceutical intermediates, improve asset integration efficiency, and optimize the governance structure of the subsidiary [4]. - The transaction has been approved by the company's board of directors and does not require shareholder approval as it does not meet the threshold for such a review [3][31][32]. - The total transaction amount is $4.29 million, which is based on an asset valuation report that assessed the market value of the subsidiary's equity at approximately ¥222.92 million [14][22]. Group 2: Related Party Transaction - BIOSYNTH LIMITED is considered a related party due to the prior directorship of Wang Wubao, who served as a director at both the company and BIOSYNTH [2][7]. - The company has not engaged in similar transactions with different related parties in the past 12 months, and the cumulative amount of daily related transactions with the same related party is ¥17.57 million [6][34]. Group 3: Financial and Operational Aspects - Shangbo Pharmaceutical focuses on CDMO services for pharmaceutical intermediates, providing integrated services for the development and production of small molecule intermediates [10]. - The subsidiary has passed various international certifications, including FDA approval, and operates under EU CGMP standards [10]. Group 4: Approval Process - The transaction was reviewed and approved in a special meeting of independent directors before being presented to the full board, where it received unanimous support [5][31].

Group 1: Key Highlights - Zhangyue Technology (掌阅科技) expects AI short drama business revenue to not exceed 1% of its main business revenue in 2025 [1][2] - Actual controller of Jialinjie (嘉麟杰), Li Zhaoting, has been subjected to compulsory measures [1][2] - Jindan Technology (金丹科技) increases investment in a project for an annual production of 75,000 tons of polylactic acid biodegradable materials [1][2] Group 2: Contract Awards - Qinglong Pipe Industry (青龙管业) wins the bid for the first section of the heat supply pipeline project from Pengyang County Wangwa Power Plant to the county [1][2] - Gaode Infrared (高德红外) signs a contract for a complete equipment system [1][2] - ST Xintong (ST信通) signs a server procurement contract worth approximately 400 million yuan [1][2] Group 3: Financial Performance - Hanzhong Precision Machinery (汉钟精机) reports a net profit of 470 million yuan for 2025, a decrease of 45.54% year-on-year [1][2] - Fudan Microelectronics (复旦微电) anticipates a net profit of approximately 232 million yuan for 2025, down about 59.42% year-on-year [1][2] - Ruilian New Materials (瑞联新材) expects a net profit of 311 million yuan for 2025, an increase of 23.48% year-on-year [1][2] Group 4: Equity Transactions - Gongjin Co. (共进股份) plans to transfer 21.8340% equity of Chip Material Technology to Xinchang Technology [1][2] - Shengquan Group (圣泉集团) intends to acquire 13.50% equity of Shangbo Pharmaceutical for 4.29 million USD [1][2] - Changjiang Communication (长江通信) plans to exit 4.66% equity of Hangzhou Chenxiao through a targeted capital reduction [1][2] Group 5: Share Buybacks - Hualing Steel (华菱钢铁) has repurchased 0.8109% of its shares [1][2] - SanNuo Bio (三诺生物) has completed a share buyback plan, repurchasing 2.81% of its shares [1][2] Group 6: Shareholding Changes - Chunqiu Electronics (春秋电子) plans to reduce holdings by no more than 2% [1][2] - Guanghuan New Network (光环新网) intends to reduce holdings by no more than 3% [1][2] - ST Yigou (ST易购) plans to reduce holdings by no more than 2.5% [1][2] - Changjiang Communication (长江通信) plans to sell no more than 1 million shares of Changfei Optical Fiber [1][2] Group 7: Other News - Yingjixin (英集芯) is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1][2] - Tianfeng Securities (天风证券) has received a notice of investigation from the China Securities Regulatory Commission [1][2] - Chuangshi Technology (创识科技) reports that its controlling shareholder has received a criminal judgment [1][2]

Group 1 - The core point of the article is that Shengquan Group announced a share acquisition agreement with Baosheng Technology, aiming to increase its stake in Jinan Shangbo Pharmaceutical Co., Ltd. from 76.5% to 90% for a transaction price of $4.29 million [1] - The acquisition is set to be completed by February 13, 2026, and will not result in any changes to the company's consolidated financial reporting scope [1] - The transaction is financed through the company's own funds, indicating a strategic move to strengthen its control over the subsidiary [1] Group 2 - The article also highlights a significant financial discrepancy within the company, noting a drastic change in net profit from a ninefold increase to a sudden loss exceeding 200 million yuan [1] - The chairman's personal investment of 50 million yuan to cover losses raises questions about the company's financial health and transparency regarding its trust investment of 5 billion yuan [1]

重要内容提示： 济南圣泉集团股份有限公司（以下简称"公司"、"圣泉集团"） 与英国宝欧信特有限公司（BIOSYNTH LIMITED）（以下简称"宝欧信 特"）于 2026 年 2 月 13 日签署《股权转让协议》，公司拟以自有资金 收购宝欧信特持有的公司控股子公司济南尚博医药股份有限公司（以 下简称"尚博医药"或"标的公司"）13.50%股权。经各方协商一致， 交易对价为 429.00 万美元。本次股权收购完成后，公司持有尚博医 药的股权比例将从 76.50%增加至 90.00%，不会导致公司合并报表范 围发生变更。 王武宝于 2025 年 3 月担任圣泉集团职工董事，于 2022 年 9 月 起担任宝欧信特董事，2026 年 1 月辞任宝欧信特董事职务，根据《上 海证券交易所股票上市规则》的相关规定，宝欧信特为公司关联方。 本次交易构成关联交易。 本次交易不构成重大资产重组。 本次交易已经公司第十届董事会 2026 年第一次独立董事专门 会议和第十届董事会第十一次会议审议通过。本次交易未达到股东会 审议标准。 证券代码：605589 证券简称：圣泉集团 公告编号：2026-006 济南圣泉集团股份有限公司 ...

Core Viewpoint - Shengquan Group (605589.SH) aims to enhance its competitiveness and operational efficiency by optimizing the governance structure of its subsidiary, Shangbo Pharmaceutical, through a share acquisition agreement with Baooushinte [1] Group 1: Share Acquisition - The company plans to acquire a 13.50% stake in its subsidiary, Shangbo Pharmaceutical, from Baooushinte using its own funds [1] - The transaction price for the share transfer is set at $4.29 million [1] Group 2: Strategic Objectives - The acquisition is intended to strengthen the synergy between fine chemicals and pharmaceutical intermediates [1] - The move is part of a broader strategy to improve asset integration efficiency and core competitiveness [1]